127 related articles for article (PubMed ID: 1746011)
1. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.
Morfini M; Lee M; Messori A
Thromb Haemost; 1991 Sep; 66(3):384-6. PubMed ID: 1746011
[No Abstract] [Full Text] [Related]
2. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
White GC; DiMichele D; Mertens K; Negrier C; Peake IR; Prowse C; Schwaab R; Yoshioka A; Ingerslev J
Thromb Haemost; 1999 Mar; 81(3):462. PubMed ID: 10102478
[No Abstract] [Full Text] [Related]
3. Registry of DNA polymorphisms within or close to the human factor VIII and factor IX genes. For the Factor VIII/IX Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Peake I
Thromb Haemost; 1992 Feb; 67(2):277-80. PubMed ID: 1352417
[No Abstract] [Full Text] [Related]
4. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
White GC; Rosendaal F; Aledort LM; Lusher JM; Rothschild C; Ingerslev J;
Thromb Haemost; 2001 Mar; 85(3):560. PubMed ID: 11307831
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of factor VIII and factor IX.
Morfini M
Haemophilia; 2003 May; 9 Suppl 1():94-9; discussion 100. PubMed ID: 12709044
[TBL] [Abstract][Full Text] [Related]
6. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of coagulation factors.
Lee M; Morfini M; Negrier C; Chamouard V
Haemophilia; 2006 Jul; 12 Suppl 3():1-7. PubMed ID: 16683990
[TBL] [Abstract][Full Text] [Related]
8. International workshop on immune tolerance induction: consensus recommendations.
DiMichele DM; Hoots WK; Pipe SW; Rivard GE; Santagostino E
Haemophilia; 2007 Jul; 13 Suppl 1():1-22. PubMed ID: 17593277
[TBL] [Abstract][Full Text] [Related]
9. The price of enhanced half-life factor IX.
Messori A; Trippoli S
Blood Transfus; 2017 Jul; 15(4):378. PubMed ID: 27893358
[No Abstract] [Full Text] [Related]
10. Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Kasper CK; Aronson DL; Davignon G; Foster P; Hillman-Wiseman C; Lusher JM; Manco-Johnson M; Meade JB; Montgomery RR; Rickles FR
Thromb Haemost; 1995 Sep; 74(3):987-9. PubMed ID: 8571334
[TBL] [Abstract][Full Text] [Related]
11. Comparative pharmacokinetic studies in haemophilia.
Morfini M
Haemophilia; 2002 Mar; 8 Suppl 2():30-3. PubMed ID: 11966850
[TBL] [Abstract][Full Text] [Related]
12. Switching to extended half-life products in Canada - preliminary data.
Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
[No Abstract] [Full Text] [Related]
13. Stretching time.
Savage N
Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
[No Abstract] [Full Text] [Related]
14. Factor VIII half-life and intensity of treatment in hemophilic patients.
Vicente V
Haematologica; 2005 Apr; 90(4):437. PubMed ID: 15820932
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII half-life and clinical phenotype of severe hemophilia A.
van Dijk K; van der Bom JG; Lenting PJ; de Groot PG; Mauser-Bunschoten EP; Roosendaal G; Grobbee DE; van den Berg HM
Haematologica; 2005 Apr; 90(4):494-8. PubMed ID: 15820945
[TBL] [Abstract][Full Text] [Related]
16. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Prowse CV
Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
[TBL] [Abstract][Full Text] [Related]
17. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
18. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.
Vlot AJ; Mauser-Bunschoten EP; Zarkova AG; Haan E; Kruitwagen CL; Sixma JJ; van den Berg HM
Thromb Haemost; 2000 Jan; 83(1):65-9. PubMed ID: 10669157
[TBL] [Abstract][Full Text] [Related]
19. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia.
Shapiro AD; Korth-Bradley J; Poon MC
Haemophilia; 2005 Nov; 11(6):571-82. PubMed ID: 16236106
[TBL] [Abstract][Full Text] [Related]
20. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
Allain JP
Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
